Evaluation of size and dose effects of rChe a 3 allergen loaded PLGA nanoparticles on modulation of Th2 immune responses by sublingual immunotherapy in mouse model of rhinitis allergic

Publication date: Available online 19 March 2019Source: International Journal of PharmaceuticsAuthor(s): Jafar Hajavi, Maryam hashemi, Mojtaba SankianGraphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research

Related Links:

Publication date: Available online 26 June 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): David Baker, Benjamin M. Jacobs, Sharmilee Gnanapavan, Klaus Schmierer, Gavin GiovannoniABSTRACTThere is increasing evidence that agents that target peripheral B cells and in some instances plasma cells can exhibit marked effects on relapsing multiple sclerosis. In addition, B cells, including plasma cells, within the central nervous system compartment are likely to play an important role in disease progression in both relapsing and progressive MS. However, current B cell-targeting antibodies may not inhibit these, bec...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
We report the measurable residual disease kinetics from a child with FLT3-internal tandem duplication acute myeloid leukemia where sequential WT1 monitoring in peripheral blood-guided withdrawal of immunosuppression.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Clinical and Laboratory Observations Source Type: research
CD19 chimeric antigen receptor T-cell (CART) therapy has revolutionized the treatment of patients with relapsed/refractory hematologic malignancies, especially B-cell acute lymphoblastic leukemia. As CART immunotherapy expands from clinical trials to FDA-approved treatments, a consensus among oncologists and hematopoietic cell transplant (HCT) physicians is needed to identify which patients may benefit from consolidative HCT post-CART therapy. Here, we review CD19 CART therapy and the outcomes of published clinical trials, highlighting the use of post-CART HCT and the pattern of relapse after CD19 CART. At this time, the l...
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Review Articles Source Type: research
UCLA has received a $10 million gift fromThe Eli and Edythe Broad Foundation to fund education, faculty recruitment and retention, and innovative research at the campus ’s stem cell research center. The foundation also announced $10 million gifts to the Broad family’s namesake stem cell research centers UC San Francisco and the University of Southern California, bringing its total support of stem cell research centers in California to $110 million since 2005.      “We are proud to support California’s growing stem cell research and treatment infrastructure led by the talented sci...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Immunotherapies are amazing drugs against cancer. However, they still fail for too many patients. This video series presents IMPRES and TIDE, two of the best predictors of cancer immunotherapy outcome... Author: Melwy Added: 06/25/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Minimal residual disease (MRD) in non Hodgkin’s lymphomas (NHLs) still represents matter of interest and debate: indeed, the new available treatments offer higher rates of complete responses and MRD negativity than in the past, with a positive impact on the long-term survival. Furthermore, the introduction of more sensitive and accurate molecular techniques, such as digital PCR (ddPCR) and the next generation sequencing techniques (NGS), increased the possibility of identifying molecular targets to be followed after therapy (such as rearrangement of immunoglobulins, fusion genes or mutations). This review focused on...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Immune-mediated dormancy is that the immune system keeps proliferating tumor cells unchanged mostly via cytotoxic activity of immune cells. Cancer dormancy, especially immune-mediated dormancy, may be the explanation for tumor refractory and be responsible for resistance to conventional chemo- and radiotherapies. Here, we will describe different scenarios of how the immune cells and cytokines involved in cancer progression are connected with the initiation of dormancy and cancer treatment. Two distinct treatments such as maintaining metastatic tumor cells dormant and awakening them are also discussed. A better understandin...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewIn the rapidly developing field of adoptive cell immunotherapy, there is urgent need for discoveries that would improve outcomes, extend the applicability, and reduce the costs. Induced pluripotent stem cells (iPSC) can be a source of broadly applicable cellular immunotherapeutics, which have been manufactured, validated, and banked in advance, and can be applied across HLA barriers. Here, we discuss the recent advances and challenges in the generation of iPSC-derived cellular products for cancer therapy.Recent FindingsiPSCs can be differentiated to functional tumor-specific T and NK cells in vitro...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Nature Reviews Clinical Oncology, Published online: 26 June 2019; doi:10.1038/s41571-019-0238-9Despite their promise, immunotherapy–radiotherapy combinations could be limited by the patient-specific nature of radiation-induced immune responses. This Review discusses methods of assessing the immune response to radiotherapy and approaches to predict the synergy between immunotherapy and radiotherapy for personalized medicine.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsThe combination of pIL-12 GET and pIRE not only enhanced survival but could bring a curative effect in wild type mice. This two-step treatment, named Immune-Gene Electro-Therapy (IGET), led to a systemic activation of the adaptive immune system and the development of an anti-tumor immune memory.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Drugs & Pharmacology | Immunotherapy | Nanotechnology